



INVITATION

BEIGENEIUS HEMATOLOGY SUMMIT

Dear colleague,

We invite you to join us for the third BeiGeneus Hematology Summit, entitled 'Relapsed/refractory CLL and indolent lymphomas: Recent advances and future challenges'. This meeting will take place at the [Lux Lisboa Park Hotel](#) in Lisbon, Portugal.

Friday, February 9, 2024 | 09:00–17:00

Saturday, February 10, 2024 | 09:15–14:00

A multidisciplinary panel is looking forward to welcoming you to 1.5 days of scientific exchange. Throughout the meeting, there will be many opportunities to make new connections with expert speakers and other hematologists from around the world.

Day 1 will feature presentations highlighting recent advances in relapsed/refractory CLL and indolent lymphomas, followed by interactive discussions and workshops where you will be able to explore the clinical implications of these advances with the experts. Audience-directed discussions and participation will be encouraged throughout the day.

On Day 2, the focus will turn to clinical trial design and statistics. Experts will demonstrate the importance of understanding the fundamental principles of good clinical trial design when interpreting clinical trials in CLL and indolent lymphomas.

We are excited to continue to grow BeiGeneus, and hope you will seize the opportunity to attend this exciting face-to-face meeting.

Yours faithfully,
The BeiGeneus Steering Committee



Francesc Bosch
Vall d'Hebron Institute of
Oncology, Spain



Christian Buske
University Hospital Ulm,
Germany



Meletios Dimopoulos
National and Kapodistrian
University of Athens School
of Medicine, Greece



Ramón García-Sanz
University Hospital of
Salamanca, Spain



Paolo Ghia
The Vita-Salute San Raffaele
University, Italy



Wojciech Jurczak
Maria Skłodowska-Curie
National Research Institute
of Oncology, Poland



Véronique Leblond
Pitié-Salpêtrière Hospital,
France



Roger Owen
Leeds Teaching Hospitals
NHS Trust, UK



Davide Rossi
Oncology Institute of Southern
Switzerland (IOSI), Switzerland



Anna Schuh
University of Oxford, UK



Stephan Stilgenbauer
University Hospital Ulm,
Germany



Alessandra Tedeschi
Niguarda Cancer Center,
Italy

[Register here](#)

DAY 1: FRIDAY, FEBRUARY 9

Time	Session title	Facilitators
09:00	Welcome and introductions	Francesc Bosch and José Carda
09:30	Icebreaker	
09:50	Recent advances in relapsed/refractory CLL	Vincent Levy
10:20	Interactive clinical scenarios: Challenges in relapsed/refractory CLL	Moderator: Francesc Bosch All panel
11:00	Coffee break	
11:20	Welcome back	Christian Buske
11:30	Recent advances in relapsed/refractory indolent lymphomas	Pier Luigi Zinzani
12:00	Audience-directed discussion: Future challenges in indolent lymphoma	All panel
12:30	Debate: Bispecific antibodies are a better therapeutic option than CAR-T therapies for early relapsing follicular lymphoma	Moderator: Christian Buske Pro: Pier Luigi Zinzani Con: Wojciech Jurczak
13:00	Lunch	
14:00	Introduction to afternoon session	Francesc Bosch
14:15	WORKSHOP SESSION 1: Relapsed/refractory CLL and indolent lymphomas	All faculty / BeiGene / Porterhouse
15:45	Coffee break	
16:05	WORKSHOP SESSION 2: Discussion of workshop findings	Moderator: Francesc Bosch Speakers: All panel
16:50	Summary, overview of Day 2 agenda, and close	Francesc Bosch
19:30	Dinner	

DAY 2: SATURDAY, FEBRUARY 10

Time	Session title	Facilitators
09:15	Welcome and introductions	José Carda
09:30	Clinical trial fundamentals: Methodology and statistics	Paolo Bruzzi
11:00	Coffee break	
11:20	Welcome back	Wojciech Jurczak and Paolo Bruzzi
11:30	WORKSHOP: Clinical trials in CLL and indolent lymphomas	All faculty / BeiGene / Porterhouse
12:45	How to improve communication between hemato-oncologists and their patients	Lesley Fallowfield
13:45	Summary and close	José Carda